Merck's potential blockbuster cholesterol pill succeeds in late-stage studies

Merck's oral cholesterol drug, enlicitide decanoate, demonstrated success in late-stage trials for treating hyperlipidemia by targeting PCSK9, potentially offering a multi-billion dollar opportunity as a non-statin alternative to injectable therapies; shares rose 2% in premarket trading. While Merck has not released specific LDL-C reduction data, analysts note AstraZeneca's AZD0780 poses a competitive threat with a 50.7% LDL-C reduction in trials, and Verve Therapeutics is developing a gene therapy for high cholesterol as well. The drug is significant for Merck as it seeks new growth drivers with Keytruda's patent expiration approaching.

Analysis

Merck has reported positive outcomes from two late-stage clinical trials for its oral cholesterol medication, enlicitide decanoate, positioning it as a potential new growth driver as the company prepares for the patent expiration of its leading cancer drug, Keytruda, by the end of the decade. The drug, designed to treat hyperlipidemia by inhibiting PCSK9, demonstrated meaningful reductions in LDL-C (low-density lipoprotein cholesterol) compared to placebo and other oral non-statin treatments, leading to a 2% increase in Merck's premarket share price. BMO Capital Markets analysts estimate this oral formulation could unlock a multi-billion dollar market opportunity, potentially broadening the PCSK9 inhibitor market currently dominated by injectables. However, Merck has not yet released specific LDL-C reduction percentages for enlicitide. This lack of detailed efficacy data is notable, especially as AstraZeneca's competing oral drug, AZD0780, has shown a 50.7% reduction in LDL-C levels in its trials, presenting a credible competitive threat according to Leerink analysts. Additionally, Verve Therapeutics is developing a gene therapy for high cholesterol, indicating an evolving and competitive landscape.

Key Decisions for Investors

• Investors should closely monitor Merck's forthcoming release of detailed LDL-C reduction data for enlicitide to accurately assess its efficacy and competitive standing against alternatives like AstraZeneca's AZD0780.
• Consider the successful trial results as a positive step in Merck's strategy to diversify revenue streams ahead of Keytruda's patent expiry, but weigh this against the competitive intensity and the current data advantage held by AstraZeneca's candidate.
• Evaluate the potential market adoption of an oral PCSK9 inhibitor, factoring in its convenience over injectables, while remaining aware of emerging innovations such as gene therapies that could reshape the long-term cholesterol treatment market.